The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across 11 distribution models in South Africa.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
07 2021
Historique:
received: 17 01 2021
revised: 29 03 2021
accepted: 31 03 2021
entrez: 19 7 2021
pubmed: 20 7 2021
medline: 7 8 2021
Statut: ppublish

Résumé

Countries around the world seek innovative ways of closing their remaining gaps towards the target of 95% of people living with HIV (PLHIV) knowing their status by 2030. Offering kits allowing HIV self-testing (HIVST) in private might help close these gaps. We analysed the cost, use and linkage to onward care of 11 HIVST kit distribution models alongside the Self-Testing AfRica Initiative's distribution of 2.2 million HIVST kits in South Africa in 2018/2019. Outcomes were based on telephonic surveys of 4% of recipients; costs on a combination of micro-costing, time-and-motion and expenditure analysis. Costs were calculated from the provider perspective in 2019 US$, as incremental costs in integrated and full costs in standalone models. HIV positivity among kit recipients was 4%-23%, with most models achieving 5%-6%. Linkage to confirmatory testing and antiretroviral therapy (ART) initiation for those screening positive was 19%-78% and 2%-72% across models. Average costs per HIVST kit distributed varied between $4.87 (sex worker model) and $18.07 (mobile integration model), with differences largely driven by kit volumes. HIVST kit costs (at $2.88 per kit) and personnel costs were the largest cost items throughout. Average costs per outcome increased along the care cascade, with the sex worker network model being the most cost-effective model across metrics used (cost per kit distributed/recipient screening positive/confirmed positive/initiating ART). Cost per person confirmed positive for HIVST was higher than standard HIV testing. HIV self-test distribution models in South Africa varied widely along four characteristics: distribution volume, HIV positivity, linkage to care and cost. Volume was highest in models that targeted public spaces with high footfall (flexible community, fixed point and transport hub distribution), followed by workplace models. Transport hub, workplace and sex worker models distributed kits in the least costly way. Distribution via index cases at facility as well as sex worker network distribution identified the highest number of PLHIV at lowest cost.

Sections du résumé

BACKGROUND
Countries around the world seek innovative ways of closing their remaining gaps towards the target of 95% of people living with HIV (PLHIV) knowing their status by 2030. Offering kits allowing HIV self-testing (HIVST) in private might help close these gaps.
METHODS
We analysed the cost, use and linkage to onward care of 11 HIVST kit distribution models alongside the Self-Testing AfRica Initiative's distribution of 2.2 million HIVST kits in South Africa in 2018/2019. Outcomes were based on telephonic surveys of 4% of recipients; costs on a combination of micro-costing, time-and-motion and expenditure analysis. Costs were calculated from the provider perspective in 2019 US$, as incremental costs in integrated and full costs in standalone models.
RESULTS
HIV positivity among kit recipients was 4%-23%, with most models achieving 5%-6%. Linkage to confirmatory testing and antiretroviral therapy (ART) initiation for those screening positive was 19%-78% and 2%-72% across models. Average costs per HIVST kit distributed varied between $4.87 (sex worker model) and $18.07 (mobile integration model), with differences largely driven by kit volumes. HIVST kit costs (at $2.88 per kit) and personnel costs were the largest cost items throughout. Average costs per outcome increased along the care cascade, with the sex worker network model being the most cost-effective model across metrics used (cost per kit distributed/recipient screening positive/confirmed positive/initiating ART). Cost per person confirmed positive for HIVST was higher than standard HIV testing.
CONCLUSION
HIV self-test distribution models in South Africa varied widely along four characteristics: distribution volume, HIV positivity, linkage to care and cost. Volume was highest in models that targeted public spaces with high footfall (flexible community, fixed point and transport hub distribution), followed by workplace models. Transport hub, workplace and sex worker models distributed kits in the least costly way. Distribution via index cases at facility as well as sex worker network distribution identified the highest number of PLHIV at lowest cost.

Identifiants

pubmed: 34275873
pii: bmjgh-2021-005019
doi: 10.1136/bmjgh-2021-005019
pmc: PMC8287621
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

©World Health Organization 2021. Licensee BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

AIDS. 2020 Nov 15;34(14):2115-2123
pubmed: 32796213
Sci Rep. 2019 Sep 2;9(1):12621
pubmed: 31477764
PLoS One. 2018 Aug 27;13(8):e0202521
pubmed: 30148846
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25255
pubmed: 30907499
BMC Med. 2016 Feb 19;14:34
pubmed: 26891969
AIDS Behav. 2019 Sep;23(Suppl 2):130-141
pubmed: 31197701
Health Econ. 2016 Feb;25 Suppl 1:95-115
pubmed: 26786617
AIDS. 2017 Jul 17;31(11):1611-1619
pubmed: 28463879
AIDS Care. 2019 Feb;31(2):186-192
pubmed: 30058362
Pan Afr Med J. 2019 Jun 04;33:83
pubmed: 31448045
PLoS One. 2018 Apr 2;13(4):e0195208
pubmed: 29608616
PLoS One. 2018 Mar 13;13(3):e0193858
pubmed: 29534077

Auteurs

Katleho Matsimela (K)

Health Economics and Epidemiology Research Office (HERO), Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Linda Alinafe Sande (LA)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, London, UK.
Department of HIV/AIDS and TB, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

Cyprian Mostert (C)

Wits Reproductive Health and HIV Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Mohammed Majam (M)

Ezintsha, Wits Reproductive Health and HIV Research Institute, University of the Witwatersrand, Johannesburg, South Africa.

Jane Phiri (J)

Ezintsha, Wits Reproductive Health and HIV Research Institute, University of the Witwatersrand, Johannesburg, South Africa.

Vincent Zishiri (V)

Ezintsha, Wits Reproductive Health and HIV Research Institute, University of the Witwatersrand, Johannesburg, South Africa.

Celeste Madondo (C)

Society for Family Health, Johannesburg, South Africa.

Stephen Khama (S)

Society for Family Health, Johannesburg, South Africa.

Thato Chidarikire (T)

HIV Prevention Programmes, National Department of Health, Pretoria, South Africa.

Marc d'Elbée (M)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, London, UK.

Karin Hatzold (K)

Population Services International, Cape Town, South Africa.

Cheryl Johnson (C)

HIV Department, World Health Organization, Geneva, Switzerland.

Fern Terris-Prestholt (F)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, London, UK.
Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.

Gesine Meyer-Rath (G)

Health Economics and Epidemiology Research Office (HERO), Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa gesine@bu.edu.
Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH